PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT3298037

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
NUPATHE INC.	03/04/2015

RECEIVING PARTY DATA

Name:	TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Street Address:	SCHLUSSELSTRASSE 12
City:	RAPPERSWIL-JONA
State/Country:	SWITZERLAND
Postal Code:	8645

PROPERTY NUMBERS Total: 18

Property Type	Number
Application Number:	60789961
Application Number:	11784526
Application Number:	12074101
Application Number:	13911808
Application Number:	14175992
Application Number:	14574927
Application Number:	60855359
Application Number:	60903934
Application Number:	60925208
Application Number:	61062069
Application Number:	61095862
Application Number:	61247168
Application Number:	61388385
Application Number:	61257418
Application Number:	61376522
Application Number:	12938136
Application Number:	14067077
Application Number:	61491661

CORRESPONDENCE DATA

PATENT REEL: 035338 FRAME: 0416

503251419

(617)607-9200 Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

617-449-6654 Phone: Email: mtierney@mccarter.com

Correspondent Name: MAUREEN TIERNEY

Address Line 1: MCCARTER & ENGLISH, LLP

Address Line 2: 265 FRANKLIN STREET

Address Line 4: BOSTON, MASSACHUSETTS 02110

ATTORNEY DOCKET NUMBER:	117723-ZECUITY
NAME OF SUBMITTER:	DANIELLE L. HERRITT
SIGNATURE:	/Danielle L. Herritt/
DATE SIGNED:	04/06/2015

Total Attachments: 12

source=Executed Zecuity IP Assignment w-Schedules A & B (Part II) 2015APR6#page1.tif source=Executed Zecuity IP Assignment w-Schedules A & B (Part II) 2015APR6#page2.tif source=Executed Zecuity IP Assignment w-Schedules A & B (Part II) 2015APR6#page3.tif source=Executed Zecuity IP Assignment w-Schedules A & B (Part II) 2015APR6#page4.tif source=Executed Zecuity IP Assignment w-Schedules A & B (Part II) 2015APR6#page5.tif source=Executed Zecuity IP Assignment w-Schedules A & B (Part II) 2015APR6#page6.tif source=Executed Zecuity IP Assignment w-Schedules A & B (Part II) 2015APR6#page7.tif source=Executed Zecuity IP Assignment w-Schedules A & B (Part II) 2015APR6#page8.tif source=Executed Zecuity IP Assignment w-Schedules A & B (Part II) 2015APR6#page9.tif source=Executed Zecuity IP Assignment w-Schedules A & B (Part II) 2015APR6#page10.tif source=Executed Zecuity IP Assignment w-Schedules A & B (Part II) 2015APR6#page11.tif source=Executed Zecuity IP Assignment w-Schedules A & B (Part II) 2015APR6#page12.tif

ASSIGNMENT OF INTELLECTUAL PROPERTY

WHEREAS, NuPathe Inc. ("Assignor"), is the current owner of the inventions which are the subject of the patents and patent applications listed on Schedule A and Schedule B and incorporated herein together with the associated know-how.

WHEREAS, Teva Pharmaceuticals International GmbH, a corporation organized and existing under the laws of Switzerland, having a place of business at Schlusselstrasse 12, 8645 Rapperswil-Jona, Switzerland ("Assignee"), desires to acquire the inventions, patents and applications listed on Schedule A and Schedule B together with the associated know-how.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor hereby assigns and transfers to Assignee, its successors, assigns and legal representatives, Assignor's entire right, title and interest in and to said inventions, patents and applications listed on Schedule A and Schedule B together with the associated know-how, including the full and exclusive rights to those inventions, applications and patents, and to any and all inventions described in those applications and patents for the United States, its territorial possessions, and/or for all foreign countries as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made, and the entire right, title and interest in and to any and all Letters Patent which may be granted therefor in the United States, its territorial possessions, and/or all foreign countries; and in and to any and all continuations, divisions, substitutes, reissues, and extensions thereof, and all other applications for Letters Patent relating thereto which have been or shall be filed in the United States, its territorial possessions, and/or any foreign countries, and all rights, including all priority rights, under any of the international conventions, unions, agreements, acts, and treaties, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made; together with all claims for damages by reason of past infringement or misappropriation of the inventions, patents, applications and associated knowhow, with the right to sue for, and collect the same, for Assignee's own use and benefit, and for the use and benefit of Assignee's successors, assigns and other legal representatives;

AND FURTHER, Assignor hereby authorizes Assignee to apply for and receive Letters Patent for such protection in its own name, in the United States, its territorial possessions, and/or in all foreign countries; and that, when requested to carry out in good faith the intent and purpose of this Assignment, at the expense of said Assignee, Assignor will execute all rightful oaths, assignments, powers of attorney and other papers necessary to secure, maintain, and enforce the patent protection for the inventions, and for vesting title to the inventions and all applications for patents on the inventions in said Assignee, its successors, assigns and legal representatives.

MEI 19786814v.1


IN WITNESS WHEREOF, Assignor has caused this Assignment of Intellectual Property to be executed and delivered this 4th day of MARCH, 2015.
Assignor: NUPATHE INC. Sum Successful Successful Secretary Assignor: NUPATHE INC. Sum Successful Secretary
On the 4 day of 1, 2015, before me personally came Brian E. Shanahan, to me known, who being by me duly sworn, executed the foregoing instrument. COMMONWEALTH OF PERSONNEL VANNA NOTARIAL SEAL NOTAR
By: David Koch Title: Managing Officer
On the day of, 2015, before me personally came David Koch, to me known, who being by me duly sworn, executed the foregoing instrument.
[Notarial Seal]Notary Public
Assignee: TEVA PHARMACEUTICALS INTERNATIONAL GMBH
By: Naama Baram Title: General Manager
On the day of, 2015, before me personally came Naama Baram, to me known, who being by me duly sworn, executed the foregoing instrument.
[Notarial Seal] Notary Public

IN WITNESS WHEREOF, As	signor has cau	sed this Assignment of Intellectual
Property to be executed and delivered this	day of	, 2015.
Assignor: NUPATHE INC.		
NOPATHE INC.		
By: Brian E. Shanahan Title: Assistant Secretary		÷-
On theday of Brian E. Shanahan, to me known, who bein instrument.	2 g by me duly s	015, before me personally came worn, executed the foregoing
[Notarial Seal]	Notary	Public
Assignee: TEVA PHARMACEUTICALS INTERNAT By: David Koch Title: Managing Officer	٨	
On the day of Monate David Koch, to me known, who being by monated Beeler (Notarial Seal)	e duly swom, s	W4
Assignee: TEVA PHARMACEUTICALS INTERNAT	•	Public H
By: Naama Baram Title: General Manager		
On the S day of Nasma Baram, to me known, who being by	(CC) y me duly swor	, 2015, before me personally came n, executed the foregoing instrument.
[Notarial Seal]	1	VVL y Public

-2-

----- MEI 19786814v.1 ------





SCHEDULE A

M&E Ref.	Country	Application No.	Filing Date	Patent No.	Issue Date	Application Title
						POLYAMINE ENHANCED
						FORMULATIONS FOR TRIPTAN
117723-02901	US	61/126811	5/7/2008			COMPOUND IONTOPHORESIS
						POLYAMINE ENHANCED
						FORMULATIONS FOR TRIPTAN
117723-02902	US	12/214555	6/19/2008	8366600	2/5/2013	COMPOUND IONTOPHORESIS
						POLYAMINE ENHANCED
						FORMULATIONS FOR TRIPTAN
117723-02903	US	13/744371	1/17/2013			COMPOUND IONTOPHORESIS
						PHARMACOKINETICS OF
						IONTOPHORETIC SUMATRIPTAN
117723-03401	US	61/126812	5/7/2008			ADMINISTRATION
						PHARMACOKINETICS OF
						IONTOPHORETIC SUMATRIPTAN
117723-03402	US	12/142604	6/19/2008	8155737	4/10/2012	ADMINISTRATION
						PHARMACOKINETICS OF
						IONTOPHORETIC SUMATRIPTAN
117723-03403	US	13/407434	2/28/2012	8597272	12/3/2013	ADMINISTRATION
						PHARMACOKINETICS OF
						IONTOPHORETIC SUMATRIPTAN
117723-03404	US	14/070198	11/1/2013			ADMINISTRATION
						PHARMACOKINETICS OF
						IONTOPHORETIC SUMATRIPTAN
117723-03405	US	14/185485	2/20/2014			ADMINISTRATION
						ELECTRONIC CONTROL OF DRUG
117723-04301	US	61/141377	12/30/2008			DELIVERY SYSTEM
						ELECTRONIC CONTROL OF DRUG
117723-04302	US	12/648726	12/29/2009			DELIVERY SYSTEM
						ELECTRONIC CONTROL OF DRUG
117723-04303	US					DELIVERY SYSTEM
						TRANSDERMAL METHODS AND
						SYSTEMS FOR THE DELIVERY OF ANTI-
117723-04401	US	60/791819	4/13/2006			MIGRAINE COMPOUNDS
						TRANSDERMAL METHODS AND
						SYSTEMS FOR THE DELIVERY OF ANTI-
117723-04402	US	60/814131	6/16/2006			MIGRAINE COMPOUNDS
						TRANSDERMAL METHODS AND
						SYSTEMS FOR THE DELIVERY OF ANTI-
117723-04403	US	12/181142	7/28/2008	7973058	7/5/2011	MIGRAINE COMPOUNDS
						TRANSDERMAL METHODS AND
			- /			SYSTEMS FOR THE DELIVERY OF ANTI-
117723-04404	US	13/105562	5/11/2011			MIGRAINE COMPOUNDS
						TRANSDERMAL METHODS AND
						SYSTEMS FOR THE DELIVERY OF ANTI-
117723-04405	US	13/105585	5/11/2011	8470853	6/25/2013	MIGRAINE COMPOUNDS
						USER-ACTIVATED SELF-CONTAINED PRE-
						PACKAGED IONTOPHORETIC DRUG
117723-04701	US	61/092284	8/27/2008		-	DELIVERY SYSTEM
						USER-ACTIVATED SELF-CONTAINED PRE-
			/ /			PACKAGED IONTOPHORETIC DRUG
117723-04702	US	61/117343	11/24/2008		1	DELIVERY SYSTEM

SCHEDULE A

						USER-ACTIVATED SELF-CONTAINED CO-
						PACKAGED IONTOPHORETIC DRUG
117723-04703	US	61/264095	11/24/2009			DELIVERY SYSTEM
						USER-ACTIVATED SELF-CONTAINED CO-
						PACKAGED IONTOPHORETIC DRUG
117723-04704	US	61/416623	11/23/2010			DELIVERY SYSTEM
						USER-ACTIVATED SELF-CONTAINED CO-
						PACKAGED IONTOPHORETIC DRUG
117723-04705	US	13/802156	3/13/2013			DELIVERY SYSTEM
						IONTOPHORETIC DRUG DELIVERY
117723-05501	US	10/371851	2/21/2003	6745071 B1	6/1/2004	SYSTEM
						TRANSDERMAL METHODS AND
						SYSTEMS FOR THE DELIVERY OF
117723-05601	US	61/250933	10/13/2009			RIZATRIPTAN
						TRANSDERMAL METHODS AND
						SYSTEMS FOR THE DELIVERY OF
117723-05602	US	12/902837	10/12/2010			RIZATRIPTAN
						THE EFFICACY AND TOLERABILITY OF
						NP101, A SUMATRIPTAN
						IONTOPHORETIC TRANSDERMAL
						PATCH, IN THE TREATMENT OF ACUTE
						MIGRAINE: A RANDOMIZED, DOUBLE-
117723-05801	US	61/232617	8/10/2009			BLIND, PLACEBO-CONTROLLED STUDY
						METHODS FOR IONTOPHORETICALLY
117723-06001	US	61/256796	10/30/2009			TREATING MIGRAINE
						METHODS FOR IONTOPHORETICALLY
117723-06002	US	61/358300	6/24/2010			TREATING NAUSEA AND MIGRAINE
						METHODS FOR IONTOPHORETICALLY
117723-06003	US	12/853922	8/10/2010	8845612	9/30/2014	TREATING NAUSEA AND MIGRAINE
						METHODS FOR IONTOPHORETICALLY
117723-06004	US	14/497595	9/26/2014			TREATING NAUSEA AND MIGRAINE
117723-06201	US					ELECTRODE PATCH CONTINUITY TESTER
						DETECTION OF PRESENCE AND
						ALIGNMENT OF A THERAPEUTIC AGENT
						IN AN IONTOPHORETIC DRUG DELIVERY
117723-06501	US	13/677089	11/14/2012			DEVICE

SCHEDULE A

M&E Ref.	Country	Application No.	Filing Date	Patent No.	Issue Date	Application Title
117722 00001	US	CO /7000C1	4/6/2006			IMPLANTS FOR THE TREATMENT OF
117723-00601	US	60/789961	4/6/2006			DOPAMINE ASSOCIATED STATES
117722 00002	US	11/784526	4/6/2007	0475930	7/2/2012	IMPLANTS FOR THE TREATMENT OF
117723-00602	03	11/764526	4/6/2007	8475829	7/2/2013	DOPAMINE ASSOCIATED STATES
117723-00603	US	12/074101	2/29/2008	8475830	7/2/2013	IMPLANTS FOR THE TREATMENT OF
117723-00003	03	12/0/4101	2/23/2008	6473630	7/2/2013	DOPAMINE ASSOCIATED STATES
117723-00604	US	13/911808	6/6/2013			IMPLANTS FOR THE TREATMENT OF
117723-00004	03	13/311808	0,0,2013			DOPAMINE ASSOCIATED STATES
117723-00605	US	14/175992	2/7/2014			IMPLANTS FOR THE TREATMENT OF
117725-00005	05	14/1/3332	2/7/2014			DOPAMINE ASSOCIATED STATES
117723-00606	LIS	14/574927	2/18/2014			IMPLANTS FOR THE TREATMENT OF
117725 00000	03	14/3/432/	2/10/2014			DOPAMINE ASSOCIATED STATES
						METHODS OF LOADING A COMPOUND
117723-01601	US	60/855359	10/27/2006			INTO AN ABSORBENT RESERVOIR
117723-02501	us	60/903934	2/28/2007			IMPLANTS FOR THE TREATMENT OF
		00/303334				PSYCHIATRIC STATES
117723-02601	us	60/925208	4/19/2007			IMPLANTS FOR THE TREATMENT OF
			1, 23, 2007			PSYCHIATRIC STATES
117723-03101	us	61/062069	1/24/2008			USER-ACTIVATED SELF-CONTAINED PRE-
		,				PACKAGED IONTOPHORETIC
117723-04801	us	61/095862	9/10/2008			IMPLANTS FOR THE TREATMENT OF
		,				DOPAMINE ASSOCIATED STATES
117723-05901	us	61/247168	9/30/2009			IMPLANTS FOR THE TREATMENT OF
		, - · · · - · ·	-,,			DOPAMINE ASSOCIATED STATES
117723-05902	us	61/388385	9/30/2010			IMPLANTS FOR THE TREATMENT OF
			-,,			DOPAMINE ASSOCIATED STATES
117723-06101	us	61/257418	11/2/2009			METHODS FOR TREATING PARKINSON'S
						DISEASE
117723-06102	us	61/376522	8/24/2010			METHODS FOR TREATING PARKINSON'S
			9,2.,,2020			DISEASE
117723-06103	us	12/938136	11/2/2010			METHODS FOR TREATING PARKINSON'S
						DISEASE
117723-06104	us	14/067077	10/30/2013			METHODS FOR TREATING PARKINSON'S
			12,30,2010			DISEASE
		l .	1			BIODEGRADABLE IMPLANTS AND USES
117723-06401	US	61/491661	5/31/2011			THEREOF

SCHEDULE B

M&E Ref.	Country	Application No.	Filing Date	Patent No.	Issue Date	Application Title
						POLYAMINE ENHANCED FORMULATIONS
117723-02920	wo	PCT/US2008/081837	10/30/2008			FOR TRIPTAN COMPOUND IONTOPHORESIS
117723-02924	AU	2008358026	12/7/2010			POLYAMINE ENHANCED FORMULATIONS FOR TRIPTAN COMPOUND IONTOPHORESIS TRANSDERMAL METHODS AND SYSTEMS
117723-02925	BR	20709965-7	12/16/2010			FOR THE DELIVERY OF ANTI-MIGRAINE
			,,			POLYAMINE ENHANCED FORMULATIONS
117723-02926	CA	2727926	12/13/2010			FOR TRIPTAN COMPOUND IONTOPHORESIS
117723-02928	CN	200880129909.X	12/17/2010	ZL200880129909.X	6/25/2014	POLYAMINE ENHANCED FORMULATIONS FOR TRIPTAN COMPOUND IONTOPHORESIS
117723 02328	CIV	200000125505.7	12/11/2010	22200880123303.X	0/23/2014	POLYAMINE ENHANCED FORMULATIONS
117723-02934	EA	201100055	1/18/2011			FOR TRIPTAN COMPOUND IONTOPHORESIS
447722 02025		0074745.6	4 /4 0 /2 04 4			POLYAMINE ENHANCED FORMULATIONS
117723-02935	EP	8874745.6	1/18/2011			FOR TRIPTAN COMPOUND IONTOPHORESIS POLYAMINE ENHANCED FORMULATIONS
117723-02939	нк	11110011.1	9/22/2011			FOR TRIPTAN COMPOUND IONTOPHORESIS
						POLYAMINE ENHANCED FORMULATIONS
117723-02940	IN	279/CHENP/2011	1/14/2011			FOR TRIPTAN COMPOUND IONTOPHORESIS POLYAMINE ENHANCED FORMULATIONS
117723-02942	IL	209755	12/5/2010	209755	10/1/2014	FOR TRIPTAN COMPOUND IONTOPHORESIS
117,723 023 12		203733	12/3/2010	203733	10/1/2011	POLYAMINE ENHANCED FORMULATIONS
117723-02943	JP	2011-514567	12/16/2010			FOR TRIPTAN COMPOUND IONTOPHORESIS
117722 02040	N 434	NAV /- /2010/012645	12/10/2010			POLYAMINE ENHANCED FORMULATIONS
117723-02948	MX	MX/a/2010/013645	12/10/2010			FOR TRIPTAN COMPOUND IONTOPHORESIS POLYAMINE ENHANCED FORMULATIONS
117723-02951	NZ	590361	1/7/2011			FOR TRIPTAN COMPOUND IONTOPHORESIS
						POLYAMINE ENHANCED FORMULATIONS
117723-02961	ZA	2010/08859	12/9/2010			FOR TRIPTAN COMPOUND IONTOPHORESIS POLYAMINE ENHANCED FORMULATIONS
117723-02976	NZ	603398	11/2/2012	603398	9/2/2014	FOR TRIPTAN COMPOUND IONTOPHORESIS
117720 02370			11, 2, 2012		5, 2, 2011	POLYAMINE ENHANCED FORMULATIONS
117723-02977	NZ	624391	5/1/2014			FOR TRIPTAN COMPOUND IONTOPHORESIS
117722 02078	CN	2.01415+11	C /C /2014			POLYAMINE ENHANCED FORMULATIONS FOR TRIPTAN COMPOUND IONTOPHORESIS
117723-02978	CIV	2.0141E+11	6/6/2014			POLYAMINE ENHANCED FORMULATIONS
117723-02980	JP	2014-147900	7/18/2014			FOR TRIPTAN COMPOUND IONTOPHORESIS
						POLYAMINE ENHANCED FORMULATIONS
117723-02999	МО	J/1508	8/27/2014		12/17/2014	FOR TRIPTAN COMPOUND IONTOPHORESIS
						PHARMACOKINETICS OF IONTOPHORETIC
117723-03420	wo	PCT/US2008/081841	10/30/2008			SUMATRIPTAN ADMINISTRATION
						DUADANA COMINISTICS OF IONITODI IODETIC
117723-03424	AU	2008358027	12/7/2010			PHARMACOKINETICS OF IONTOPHORETIC SUMATRIPTAN ADMINISTRATION
117723 03424	10	2000330027	12,7,2010			TRANSDERMAL METHODS AND SYSTEMS
						FOR THE DELIVERY OF ANTI-MIGRAINE
117723-03425	BR	PI0709965-7	12/16/2010			COMPOUNDS
						PHARMACOKINETICS OF IONTOPHORETIC
117723-03426	CA	2727927	12/13/2010			SUMATRIPTAN ADMINISTRATION
						DUADNA COMINETICS OF IONTODICOSTIC
117723-03434	EA	201100056	1/18/2011			PHARMACOKINETICS OF IONTOPHORETIC SUMATRIPTAN ADMINISTRATION
11,,25 05454		201100000	2, 10, 2011			SOUTH THE PROPERTY OF THE PROP
			1.			PHARMACOKINETICS OF IONTOPHORETIC
117723-03435	EP	8874746.4	1/18/2011			SUMATRIPTAN ADMINISTRATION
						PHARMACOKINETICS OF IONTOPHORETIC
117723-03439	нк	11110589.3	1/18/2011			SUMATRIPTAN ADMINISTRATION
						DUADNA COMMETICO OF IONITODINOSETIO
117723-03442	IL	209756	12/5/2010			PHARMACOKINETICS OF IONTOPHORETIC SUMATRIPTAN ADMINISTRATION
111/123-03442	I I'F	1203130	112/3/2010	1	<u> </u>	POWATRIC FAIN ADMINISTRATION

	T	1	1	1	Τ	T
117723-03443	JP	2011-514568	12/16/2010	5662312	12/12/2014	PHARMACOKINETICS OF IONTOPHORETIC SUMATRIPTAN ADMINISTRATION
117723-03448	мх	MX/a/2010/013644	12/10/2010			PHARMACOKINETICS OF IONTOPHORETIC SUMATRIPTAN ADMINISTRATION
117723-03449	мх	MX/a/2014/012845	10/23/2014			PHARMACOKINETICS OF IONTOPHORETIC SUMATRIPTAN ADMINISTRATION
117723-03451	NZ	590356	1/7/2011	590356	3/1/2013	PHARMACOKINETICS OF IONTOPHORETIC SUMATRIPTAN ADMINISTRATION
117723-03461	ZA	2010/08860	12/9/2010			PHARMACOKINETICS OF IONTOPHORETIC SUMATRIPTAN ADMINISTRATION
117723-03477	JP	2014-245880	12/4/2014			PHARMACOKINETICS OF IONTOPHORETIC SUMATRIPTAN ADMINISTRATION
117723-04320	wo	PCT/US2009/069673	12/29/2009			ELECTRONIC CONTROL OF DRUG DELIVERY SYSTEM ELECTRONIC CONTROL OF DRUG DELIVERY
117723-04324	AU	2009335085	7/28/2011			SYSTEM ELECTRONIC CONTROL OF DRUG DELIVERY
117723-04325	BR	PI0923808-5	6/30/2011			SYSTEM ELECTRONIC CONTROL OF DRUG DELIVERY
117723-04326	CA	2748569	6/28/2011	71 2000901 57664 6	2/26/2014	SYSTEM ELECTRONIC CONTROL OF DRUG DELIVERY
117723-04328	CN EA	2.0098E+11 201100891	8/29/2011 6/30/2011	ZL200980157664.6	3/26/2014	SYSTEM ELECTRONIC CONTROL OF DRUG DELIVERY SYSTEM
117723-04335	EP	9803973.8	8/1/2011	2393549	10/1/2014	ELECTRONIC CONTROL OF DRUG DELIVERY SYSTEM
117723-04340	IN	5478/CHENP/2011	1/12/2012			ELECTRONIC CONTROL OF DRUG DELIVERY SYSTEM ELECTRONIC CONTROL OF DRUG DELIVERY
117723-04342	IL	213855	6/30/2011			SYSTEM ELECTRONIC CONTROL OF DRUG DELIVERY
117723-04343	JP	2011-544581	6/29/2011		1	SYSTEM ELECTRONIC CONTROL OF DRUG DELIVERY
117723-04348	MX NZ	MX/a/2011/007137 593928	6/30/2011 7/7/2011	320060 593928	5/12/2014 7/1/2014	SYSTEM ELECTRONIC CONTROL OF DRUG DELIVERY SYSTEM
117723-04361	ZA	2011/04832	6/30/2011	333320	77 17 2011	ELECTRONIC CONTROL OF DRUG DELIVERY SYSTEM
117723-04376	нк	12103810.8	4/18/2012			ELECTRONIC CONTROL OF DRUG DELIVERY SYSTEM
117723-04378	CN	2.0141E+11	3/11/2014			IONTOPHORETIC DRUG DELIVERY SYSTEM ELECTRONIC CONTROL OF DRUG DELIVERY
117723-04379	EP	14180005.2	8/6/2014			SYSTEM ELECTRONIC CONTROL OF DRUG DELIVERY
117723-04381 117723-04383	DE ES	6.02009E+11 9803973.8	8/1/2011 8/1/2011	2393549	10/1/2014	SYSTEM ELECTRONIC CONTROL OF DRUG DELIVERY SYSTEM
117723-04385	FR	9803973.8	8/1/2011	2393549	10/1/2014	ELECTRONIC CONTROL OF DRUG DELIVERY SYSTEM
117723-04386	GB	9803973.8	8/1/2011	2393549	10/1/2014	ELECTRONIC CONTROL OF DRUG DELIVERY SYSTEM
117723-04387	TR	9803973.8	8/1/2011	2393549	10/1/2014	ELECTRONIC CONTROL OF DRUG DELIVERY SYSTEM ELECTRONIC CONTROL OF DRUG DELIVERY
117723-04390	IT	9803973.8	8/1/2011	2393549	10/1/2014	SYSTEM ELECTRONIC CONTROL OF DRUG DELIVERY
117723-04393	NL	9803973.8	8/1/2011	2393549	10/1/2014	SYSTEM

19789635_1.xlsx 2 PATENT REEL: 035338 FRAME: 0426

SCHEDULE B

	1	1	1			TELECTRONIC CONTROL OF DRUG DELIVERY
117723-04394	NZ	622157	3/11/2014			SYSTEM
						ELECTRONIC CONTROL OF DRUG DELIVERY
117723-04395	NZ	700441	9/26/2014			SYSTEM
						TRANSDERMAL METHODS AND SYSTEMS
						FOR THE DELIVERY OF ANTI-MIGRAINE
117723-04420	wo	PCT/US2007/009000	4/12/2007			COMPOUNDS
						TRANSDERMAL METHODS AND SYSTEMS
117722 04421		20072220005	10/2/2008	20072220605	1/2/2012	FOR THE DELIVERY OF ANTI-MIGRAINE
117723-04421	AU	2007238685	10/3/2008	2007238685	1/3/2013	COMPOUNDS TRANSDERMAL METHODS AND SYSTEMS
						FOR THE DELIVERY OF ANTI-MIGRAINE
117723-04422	BR	PI0709965-7	10/13/2008			COMPOUNDS
			10,10,100			TRANSDERMAL METHODS AND SYSTEMS
						FOR THE DELIVERY OF ANTI-MIGRAINE
117723-04423	CA	2650412	10/8/2008			COMPOUNDS
						TRANSDERMAL METHODS AND SYSTEMS
						FOR THE DELIVERY OF ANTI-MIGRAINE
117723-04424	CN	2.0078E+11	12/15/2008	ZL200780022405.3	4/23/2014	COMPOUNDS
						TRANSDERMAL METHODS AND SYSTEMS
117723-04425	l.,	200000115	44/40/2222			FOR THE DELIVERY OF ANTI-MIGRAINE
	EA	200802146	11/13/2008		1	COMPOUNDS TRANSDERMAL METHODS AND SYSTEMS
						FOR THE DELIVERY OF ANTI-MIGRAINE
117723-04426	EP	7755312.1	11/13/2008			COMPOUNDS
117723-04420	L1	7733312.1	11/13/2008		+	COMIT GOINDS
						TRANSDERMAL PATCHES FOR THE DELIVERY
117723-04427	IL	194553	10/6/2008			OF ANTI-MIGRAINE COMPOUNDS
						TRANSDERMAL METHODS AND SYSTEMS
						FOR THE DELIVERY OF ANTI-MIGRAINE
117723-04428	IN	6176/CHENP/2008	11/12/2008			COMPOUNDS
						TRANSDERMAL METHODS AND SYSTEMS
447700 04400			10/10/2000	5500040	7/10/2014	FOR THE DELIVERY OF ANTI-MIGRAINE
117723-04429	JP	2009-505469	10/10/2008	5580042	7/18/2014	COMPOUNDS TRANSDERMAL METHODS AND SYSTEMS
						FOR THE DELIVERY OF ANTI-MIGRAINE
117723-04430	l _{MX}	MX/a/2008/012922	10/7/2008	305988	12/10/2012	COMPOUNDS
11//25 01150		1111/4 4/ 2000/ 012322	10,7,2000	00000	12, 10, 2012	TRANSDERMAL METHODS AND SYSTEMS
						FOR THE DELIVERY OF ANTI-MIGRAINE
117723-04431	NZ	572357	10/29/2008			COMPOUNDS
						TRANSDERMAL METHODS AND SYSTEMS
						FOR THE DELIVERY OF ANTI-MIGRAINE
117723-04432	ZA	2008/08428	10/2/2008			COMPOUNDS
						TRANSDERMAL METHODS AND SYSTEMS
117722 04422	нк	0104596.3	F /20 /2000			FOR THE DELIVERY OF ANTI-MIGRAINE COMPOUNDS
117723-04433	IUV	9104586.3	5/20/2009			TRANSDERMAL METHODS AND SYSTEMS
						FOR THE DELIVERY OF ANTI-MIGRAINE
117723-04476	l _{NZ}	596498	11/17/2011	596498	9/3/2013	COMPOUNDS
	1				-,-,	TRANSDERMAL METHODS AND SYSTEMS
						FOR THE DELIVERY OF ANTI-MIGRAINE
117723-04477	AU	2012261753	12/11/2012		<u> </u>	COMPOUNDS
						TRANSDERMAL METHODS AND SYSTEMS
	1		1			FOR THE DELIVERY OF ANTI-MIGRAINE
			5/20/2013	1		COMPOUNDS
117723-04478	NZ	610790	3/20/2013	1		
117723-04478	NZ	610790	3/20/2013			TRANSDERMAL METHODS AND SYSTEMS
						FOR THE DELIVERY OF ANTI-MIGRAINE
117723-04478 117723-04479	NZ CN	610790 2.0141E+11	3/24/2014			FOR THE DELIVERY OF ANTI-MIGRAINE COMPOUNDS
						FOR THE DELIVERY OF ANTI-MIGRAINE COMPOUNDS TRANSDERMAL METHODS AND SYSTEMS
117723-04479	CN	2.0141E+11	3/24/2014			FOR THE DELIVERY OF ANTI-MIGRAINE COMPOUNDS TRANSDERMAL METHODS AND SYSTEMS FOR THE DELIVERY OF ANTI-MIGRAINE
						FOR THE DELIVERY OF ANTI-MIGRAINE COMPOUNDS TRANSDERMAL METHODS AND SYSTEMS
117723-04479	CN	2.0141E+11	3/24/2014			FOR THE DELIVERY OF ANTI-MIGRAINE COMPOUNDS TRANSDERMAL METHODS AND SYSTEMS FOR THE DELIVERY OF ANTI-MIGRAINE COMPOUNDS

	1			1		USER-ACTIVATED SELF-CONTAINED CO-
						PACKAGED IONTOPHORETIC DRUG
117723-04724	AU	2011332187	4/12/2013			DELIVERY SYSTEM
						USER-ACTIVATED SELF-CONTAINED CO-
447722 04725		DD442042042447.2	F /4 F /2042			PACKAGED IONTOPHORETIC DRUG
117723-04725	BR	BR112013012117-3	5/15/2013			DELIVERY SYSTEM USER-ACTIVATED SELF-CONTAINED CO-
						PACKAGED IONTOPHORETIC DRUG
117723-04726	CA	2817824	5/13/2013			DELIVERY SYSTEM
						USER-ACTIVATED SELF-CONTAINED CO-
						PACKAGED IONTOPHORETIC DRUG
117723-04728	CN	2.0118E+11	5/21/2013			DELIVERY SYSTEM
						USER-ACTIVATED SELF-CONTAINED CO-
117722 04724	-^	201200745	6/10/2012			PACKAGED IONTOPHORETIC DRUG
117723-04734	EA	201390745	6/19/2013			DELIVERY SYSTEM USER-ACTIVATED SELF-CONTAINED CO-
						PACKAGED IONTOPHORETIC DRUG
117723-04735	EP	11788281.1	6/21/2013			DELIVERY SYSTEM
						USER-ACTIVATED SELF-CONTAINED CO-
						PACKAGED IONTOPHORETIC DRUG
117723-04739	НК	14103138.1	4/2/2014			DELIVERY SYSTEM USER-ACTIVATED SELF-CONTAINED CO-
						PACKAGED IONTOPHORETIC DRUG
117723-04740	IN	4026/DELNP/2013	5/3/2013			DELIVERY SYSTEM
117723-04740		4020/DELINI/2013	3/3/2013			USER-ACTIVATED SELF-CONTAINED CO-
						PACKAGED IONTOPHORETIC DRUG
117723-04742	IL	226067	4/30/2013			DELIVERY SYSTEM
						USER-ACTIVATED SELF-CONTAINED CO-
			1			PACKAGED IONTOPHORETIC DRUG
117723-04743	JP	2013-539900	5/21/2013			DELIVERY SYSTEM USER-ACTIVATED SELF-CONTAINED CO-
						PACKAGED IONTOPHORETIC DRUG
117723-04748	l _{MX}	MX/a/2013/005430	5/15/2013			DELIVERY SYSTEM
117723-04748	IVIX	1417/4/2013/003430	3/13/2013			USER-ACTIVATED SELF-CONTAINED CO-
						PACKAGED IONTOPHORETIC DRUG
117723-04751	NZ	610305	5/9/2013			DELIVERY SYSTEM
						USER-ACTIVATED SELF-CONTAINED CO-
	<u> </u>		_ /- /			PACKAGED IONTOPHORETIC DRUG
117723-04761	ZA	2013/03221	5/3/2013			DELIVERY SYSTEM TRANSDERMAL METHODS AND SYSTEMS
117723-05620	lwo	PCT/US2010/052314	10/12/2010			FOR THE DELIVERY OF RIZATRIPTAN
117723 03020		1 01/032010/032314	10/12/2010			METHODS FOR IONTOPHORETICALLY
117723-06020	wo	PCT/US2010/045045	8/10/2010			TREATING NAUSEA AND MIGRAINE
						METHODS FOR IONTOPHORETICALLY
117723-06024	AU	2010282660	2/10/2012			TREATING NAUSEA AND MIGRAINE
117722 00025		DD112012002111 2	2/10/2012			METHODS FOR IONTOPHORETICALLY
117723-06025	BR	BR112012003111-2	2/10/2012			TREATING NAUSEA AND MIGRAINE METHODS FOR IONTOPHORETICALLY
117723-06026	CA	2770211	2/3/2012			TREATING NAUSEA AND MIGRAINE
1111120 00020	1					METHODS FOR IONTOPHORETICALLY
117723-06028	CN	201080045696.X	4/10/2012			TREATING NAUSEA AND MIGRAINE
						METHODS FOR IONTOPHORETICALLY
117723-06034	EA	201270227	2/28/2012			TREATING NAUSEA AND MIGRAINE
117722 00025		10000630.0	2/6/2012			METHODS FOR IONTOPHORETICALLY
117723-06035	EP	10808639.8	3/6/2012	+		TREATING NAUSEA AND MIGRAINE METHODS FOR IONTOPHORETICALLY
117723-06039	нк	12112833.2	12/12/2012			TREATING NAUSEA AND MIGRAINE
	<u> </u>					METHODS FOR IONTOPHORETICALLY
117723-06042	IL	217935	2/5/2012			TREATING NAUSEA AND MIGRAINE
						METHODS FOR IONTOPHORETICALLY
117723-06043	JP	2012-524789	2/8/2012			TREATING NAUSEA AND MIGRAINE
		500022	2/7/2012	F09633	61412044	METHODS FOR IONTOPHORETICALLY
	NZ	598622	3/7/2012	598622	6/4/2014	TREATING NAUSEA AND MIGRAINE
117723-06051	1112	333322	1			METHODS FOR IONTOPHORETICALLY

Zecuity IP Portfolio PCT/Foreign Patents/Applications

SCHEDULE B

117723-06201	US				ELECTRODE PATCH CONTINUITY TESTER
117723-06520	wo	PCT/US2013/070068	11/14/2013		DETECTION OF PRESENCE AND ALIGNMENT OF A THERAPEUTIC AGENT IN AN IONTOPHORETIC DRUG DELIVERY DEVICE
117723-06551	NZ	629841	9/2/2014		DETECTION OF PRESENCE AND ALIGNMENT OF A THERAPEUTIC AGENT IN AN IONTOPHORETIC DRUG DELIVERY DEVICE

5 19789635_1.xlsx **RECORDED: 04/06/2015**